Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
Long-term disease-free survival in adults with T-cell acute lymphoblastic leukemia (T-ALL) remains poor, particularly after relapse, with few available salvage options. Preclinical data suggest that inhibition of the antiapoptotic protein BCL-2 (B-cell lymphoma 2) either alone or in combination with...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/6092646 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305109131952128 |
|---|---|
| author | Leena T. Rahmat Anna Nguyen Haifaa Abdulhaq Sonam Prakash Aaron C. Logan Gabriel N. Mannis |
| author_facet | Leena T. Rahmat Anna Nguyen Haifaa Abdulhaq Sonam Prakash Aaron C. Logan Gabriel N. Mannis |
| author_sort | Leena T. Rahmat |
| collection | DOAJ |
| description | Long-term disease-free survival in adults with T-cell acute lymphoblastic leukemia (T-ALL) remains poor, particularly after relapse, with few available salvage options. Preclinical data suggest that inhibition of the antiapoptotic protein BCL-2 (B-cell lymphoma 2) either alone or in combination with other agents, may be a unique therapeutic approach for the treatment of T-ALL. We present a case of a young male with T-ALL, relapsed after allogeneic hematopoietic stem cell transplant, who achieved a second complete remission following salvage therapy with combined venetoclax and decitabine. Assessment of measurable residual disease by next generation sequencing showed no evidence of residual disease of a sensitivity of 1 × 10−6. While the combination of venetoclax and hypomethylating agents has shown promise in the treatment of relapsed/refractory AML, and to our knowledge, this is the first report of this combination demonstrating clinical activity in relapsed/refractory T-ALL. |
| format | Article |
| id | doaj-art-3cf595672fa54626a4df911db411bc36 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-3cf595672fa54626a4df911db411bc362025-08-20T03:55:33ZengWileyCase Reports in Hematology2090-65602090-65792018-01-01201810.1155/2018/60926466092646Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell TransplantLeena T. Rahmat0Anna Nguyen1Haifaa Abdulhaq2Sonam Prakash3Aaron C. Logan4Gabriel N. Mannis5Department of Hematologic Malignancies and Blood and Marrow Transplant, University of California, San Francisco, CA, USADepartment of Pathology, University of California, San Francisco, CA, USADepartment of Hematology and Oncology, University of California, San Francisco, CA, USADepartment of Pathology, University of California, San Francisco, CA, USADepartment of Hematologic Malignancies and Blood and Marrow Transplant, University of California, San Francisco, CA, USADepartment of Hematologic Malignancies and Blood and Marrow Transplant, University of California, San Francisco, CA, USALong-term disease-free survival in adults with T-cell acute lymphoblastic leukemia (T-ALL) remains poor, particularly after relapse, with few available salvage options. Preclinical data suggest that inhibition of the antiapoptotic protein BCL-2 (B-cell lymphoma 2) either alone or in combination with other agents, may be a unique therapeutic approach for the treatment of T-ALL. We present a case of a young male with T-ALL, relapsed after allogeneic hematopoietic stem cell transplant, who achieved a second complete remission following salvage therapy with combined venetoclax and decitabine. Assessment of measurable residual disease by next generation sequencing showed no evidence of residual disease of a sensitivity of 1 × 10−6. While the combination of venetoclax and hypomethylating agents has shown promise in the treatment of relapsed/refractory AML, and to our knowledge, this is the first report of this combination demonstrating clinical activity in relapsed/refractory T-ALL.http://dx.doi.org/10.1155/2018/6092646 |
| spellingShingle | Leena T. Rahmat Anna Nguyen Haifaa Abdulhaq Sonam Prakash Aaron C. Logan Gabriel N. Mannis Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant Case Reports in Hematology |
| title | Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant |
| title_full | Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant |
| title_fullStr | Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant |
| title_full_unstemmed | Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant |
| title_short | Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant |
| title_sort | venetoclax in combination with decitabine for relapsed t cell acute lymphoblastic leukemia after allogeneic hematopoietic cell transplant |
| url | http://dx.doi.org/10.1155/2018/6092646 |
| work_keys_str_mv | AT leenatrahmat venetoclaxincombinationwithdecitabineforrelapsedtcellacutelymphoblasticleukemiaafterallogeneichematopoieticcelltransplant AT annanguyen venetoclaxincombinationwithdecitabineforrelapsedtcellacutelymphoblasticleukemiaafterallogeneichematopoieticcelltransplant AT haifaaabdulhaq venetoclaxincombinationwithdecitabineforrelapsedtcellacutelymphoblasticleukemiaafterallogeneichematopoieticcelltransplant AT sonamprakash venetoclaxincombinationwithdecitabineforrelapsedtcellacutelymphoblasticleukemiaafterallogeneichematopoieticcelltransplant AT aaronclogan venetoclaxincombinationwithdecitabineforrelapsedtcellacutelymphoblasticleukemiaafterallogeneichematopoieticcelltransplant AT gabrielnmannis venetoclaxincombinationwithdecitabineforrelapsedtcellacutelymphoblasticleukemiaafterallogeneichematopoieticcelltransplant |